Key terms
About TAK
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TAK news
Yesterday
9:00pm ET
Takeda Announces Issuance of Innovative Hybrid Bonds
Apr 08
8:05am ET
Takeda selects eight U.S. non-profit organizations as grant recipients
Mar 27
11:32am ET
Takeda Reveals Board Candidates for Shareholders’ Vote
Mar 20
9:06am ET
Scilex announces agreement with Takeda to resolve patent infringement lawsuit
Mar 19
12:23pm ET
Takeda announces FDA approval of supplemental indication for Iclusig
Mar 19
11:31am ET
Takeda leukemia treatment granted accelerated approval by FDA
Mar 19
6:32am ET
Centogene extends partnership with Takeda
Mar 18
7:10am ET
Protagonist closes rusfertide license, collaboration agreement with Takeda
Mar 13
8:12am ET
Takeda announces results from Phase 2 study of mezagitamab as antibody for ITP
Mar 08
11:16am ET
Takeda price target raised to $14.30 from $13.70 at JPMorgan
Feb 27
5:37am ET
Takeda, Biological E. Limited collaborate to accelerate access to Dengue vaccine
Feb 12
8:05am ET
FDA approvesTakeda’s Eohilia for eosinophilic esophagitis treatment
Feb 08
6:02pm ET
Takeda to rapidly initiate the first global Phase 3 trials of TAK-861
Feb 01
5:43am ET
Takeda announces CFO Costa Saroukos to leave, Milano Furuta to succeed
Jan 31
6:41pm ET
Protagonist Therapeutics, Takeda enter into license agreement for Rusfertide
Jan 29
4:30pm ET
Halozyme announces Takeda received EC approval for HYQVIA
Jan 25
9:25am ET
Guggenheim ups CymaBay price target to $28, sees M&A potential
No recent press releases are available for TAK
TAK Financials
Key terms
Ad Feedback
TAK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TAK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
